Retro Bio, backed by OpenAI's Sam Altman, is approaching what could become one of the drug industry's largest funding rounds.

The full details are currently accessible only to STAT+ subscribers behind a paywall.

The company plans to combine epigenetic editing with cell replacement therapies to rejuvenate aging tissues and extend human lifespan by roughly a decade.

Slide decks reviewed by STAT imply Retro Bio’s market value could rival major pharma players and approach the scale of tech giants like Alphabet or Microsoft, signaling bold market ambitions.

Funding materials describe longevity as potentially the greatest pharma market ever, underscoring Silicon Valley’s strong interest in aging as a frontier for investment.